(Q37810596)

23 August 2017

title

Physiology and pathophysiology of the RANKL/RANK system (English)

1 reference

23 August 2017

1 reference

3

0 references

Toshikatsu Hanada

series ordinal

2

object named as

Toshikatsu Hanada

1 reference

23 August 2017

Reiko Hanada

1

1 reference

23 August 2017

publication date

1 December 2010

1 reference

23 August 2017

1 reference

23 August 2017

volume

391

1 reference

23 August 2017

issue

12

1 reference

23 August 2017

page(s)

1365-1370

1 reference

A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function

23 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1515%2FBC.2010.149

Bone versus immune system

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBC.2010.149

Control of mammary stem cell function by steroid hormone signalling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBC.2010.149

Effects of denosumab on bone mineral density and bone turnover in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBC.2010.149

Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBC.2010.149

Denosumab for prevention of fractures in postmenopausal women with osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBC.2010.149

The RANK/RANKL/OPG triad in cancer-induced bone diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBC.2010.149

RANK is essential for osteoclast and lymph node development

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBC.2010.149

Mechanisms of CNS response to systemic immune challenge: the febrile response

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBC.2010.149

The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBC.2010.149

Human osteoclast-poor osteopetrosis with hypogammaglobulinemia due to TNFRSF11A (RANK) mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBC.2010.149

Molecular mechanisms of osteolytic bone metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBC.2010.149

Central control of fever and female body temperature by RANKL/RANK

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBC.2010.149

Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBC.2010.149

Mutations in TNFRSF11A, affecting the signal peptide of RANK, cause familial expansile osteolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBC.2010.149

Crystal structure of the extracellular domain of mouse RANK ligand at 2.2-A resolution

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBC.2010.149

Regulation of cancer cell migration and bone metastasis by RANKL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBC.2010.149

Progesterone induces adult mammary stem cell expansion

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBC.2010.149

The genetic transformation of bone biology

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBC.2010.149

Reaching a genetic and molecular understanding of skeletal development

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBC.2010.149

Localization of RANKL (receptor activator of NF kappa B ligand) mRNA and protein in skeletal and extraskeletal tissues.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBC.2010.149

Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBC.2010.149

OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBC.2010.149

Challenges to defining a role for progesterone in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBC.2010.149

RANK/RANKL: regulators of immune responses and bone physiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBC.2010.149

RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBC.2010.149

Epidermal RANKL controls regulatory T-cell numbers via activation of dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBC.2010.149

Cytokines and fever. Mechanisms and sites of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBC.2010.149

Denosumab in postmenopausal women with low bone mineral density

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBC.2010.149

Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBC.2010.149

Central control of thermogenesis in mammals

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBC.2010.149

Metastasis to bone: causes, consequences and therapeutic opportunities

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBC.2010.149

RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBC.2010.149

Therapeutic approaches to bone diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBC.2010.149

RANK signals from CD4(+)3(-) inducer cells regulate development of Aire-expressing epithelial cells in the thymic medulla

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBC.2010.149

Osteoprotegerin: a novel secreted protein involved in the regulation of bone density

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBC.2010.149

Denosumab in men receiving androgen-deprivation therapy for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBC.2010.149

Osteoclast-poor human osteopetrosis due to mutations in the gene encoding RANKL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBC.2010.149

Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBC.2010.149

Genetic regulation of osteoclast development and function

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBC.2010.149

Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBC.2010.149

TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBC.2010.149

Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBC.2010.149

Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBC.2010.149

Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: A twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBC.2010.149

21 January 2018

Identifiers

DOI

10.1515/BC.2010.149

1 reference

23 August 2017

1 reference